Evaluation and Prediction of Fluoroquinolone Pharmacodynamics in Bacterial Keratitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 5, 2003, Pages 493-499

  Wilhelmus, Kirk R ^a,b  

^a CULLEN EYE INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BIOAVAILABILITY; DRUG SCREENING; EYE INFECTION; FEMALE; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTION;

EID: 0142182393     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803322473042     Document Type: Article

References (34)

1. Jones, D.B. Emerging antibiotic resistance: real and relative. Arch. Ophthalmol. 114:91-92, 1996.
2. Kowalski, R.P., Karenchak, L.M., and Eller, A.W. The role of ciprofloxacin in endophthalmitis therapy. Am. J. Ophthalmol. 116:695-699, 1993.
3. Diamond, J.P., White, L., Leeming, J.P., Bing Hoh, H., and Easty, D.L. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br. J. Ophthalmol. 79:606-609, 1995.
4. Kowalski, R.P., Karenchak, L.M., and Gordon, Y.J. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea. 17:282-287, 1998.
5. Jones, D.B. A plan for antimicrobial therapy in bacterial keratitis. Trans. Am. Acad. Ophthalmol. Otolaryngol. 79:95-103, 1975.
6. Rotschafer, J.C., Walker, K.J., Madras-Kelly, K.J., and Sullivan, C.J. Antibiotic pharmacodynamics. In: Cutler, N.R., Sramek, J.J., and Narang, P.K., eds. Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology. Chichester: John Wiley & Sons 1994:315-343.
7. Amsden, G.W., Ballow, C.H., and Bertino, J.S. Jr. Pharmacokinetics and pharmacodynamics of anti-infective agents. In: Mandell, G.L., Bennett, J.E. and Dolin, R., eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 2000:253-261.
8. Gunderson, B.W., Ross, G.H., Ibrahim, K.H., and Rotschafer, J.C. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy. 21(11[pt. 2]):302S-318S, 2001.
9. Nightingale, C.H., and Murakawa, T. Microbiology and pharmacokinetics. In: Nightingale, C.H., Murakwa, T. and Ambrose, P.G., eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker, 2002:23-39.
10. Ellner, P.D., and Neu, H.C. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578, 1981.
11. Barriere, S.L., Ely, E., Kapusnik, J.E., and Gambertoglio, J.G. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J. Antimicrob. Chemother. 16:49-59, 1985.
12. Polk, R. Optimal use of modern antibiotics: emerging trends. Clin. Infect. Dis. 29:264-274, 1999.
13. McDermott, M.L., Tran, T.D., Cowden, J.W., and Buggé, C.J.L. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology. 100: 197-200, 1993.
14. Price, F.W. Jr., Whitson, W.E., Collins, K.S., and Gonzales, J.S. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 14:152-156, 1995.
15. Badenoch, P.R., McDonald, P.J., and Coster, D.J. Effect of inflammation on antibiotic penetration into the anterior segment of the rat eye. Invest. Ophthalmol. Vis. Sci. 27:958-965, 1986.
16. Hobden, J.A., O'Callaghan, R.J., Insler, M.S., and Hill, J.M. Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. Cornea. 12:138-141, 1993.
17. Donnenfeld, E.D., Perry, H.D., Snyder, R.W., Moadel, R., Elsky, M., and Jones, H. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch. Ophthalmol. 115:173-176, 1997.
18. Wilhelmus, K.R., Abshire, R.L., and Schlech, B.A. The influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch. Ophthalmol. 2003, in press.
19. StataCorp. Stata Statistical Software, Release 8. Stata Corporation, College Station, TX, 2003.
20. Steinberg, D., and Colla, P. CART-Classification and Regression Trees, Version 4.0. Salford Systems, San Diego, CA, 1997.
21. Li, R.C., Zhu, M. and Schentag, J.J. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Pharmacokinet. 37:1-16, 1999.
22. Lode, H., Borner, K., and Koeppe, P. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27:33-39, 1998.
23. Wright, D.H., Brown, G.H., Peterson, M.L., and Rotschafer, J.C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683, 2000.
24. Rodvold, K.A., and Neuhauser, M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21:233S-252S, 2001.
25. Owens, R.C. Jr., and Ambrose, P.G. Pharmacodynamics of quinolones. In: Nightingale, C.H., Murakawa, T., and Ambrose, P.G., eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker, 2002:155-176.
26. Preston, S.L., Drusano, G.L., Berman, A.L., Fowler, C.L., Chow, A.T., Dornseif, B., Reichl, V., Natarajan, J., and Corrado, M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 279:125-129, 1998.
27. Thomas, J.K., Forrest, A., Bhavnani, S.M., Hyatt, J.M., Cheng, A., Ballow, C.H., and Schentag, J.J. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527, 1998.
28. Zhanel, G.G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A.S., Embil, J., Smith, H., and Hoban, D.J. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 62:13-59, 2002.
29. Gould, I.M. Determinants of response to antibiotic therapy. J. Chemother. 10:347-353, 1998.
30. Schentag, J.J., and Nix, D.E. Pharmacokinetics and tissue penetration of quinolones. In: Siporin, C., Heifetz, C.L. and Domagala, J.M., eds. The New Generation of Quinolones. New York: Marcel Dekker, 1990:189-222.
31. Hooper, D.C. Mechanisms of fluoroquinolone resistance. Drug Resist. Updat. 2:38-55, 1999.
32. Sanders, C.C. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin. Infect. Dis. 32(Suppl 1):1-8, 2001.
33. Zeiler, H.J., and Voigt, W.H. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. Am. J. Med. 82 (suppl. 4A):87-90, 1987.
34. Frimodt-Møller, N. How predictive is PT/PD for antibacterial agents? Int. J. Antimicrob. Agents. 19:333-339, 2002.